Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study.

Trial Profile

Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EOS
  • Sponsors ALTANA Pharma
  • Most Recent Events

    • 07 May 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Based on results of this trial, roflumilast has been recommended for approval in the EU, by the European Medicines Agency's (EMA), according to a Nycomed media release.
    • 05 Nov 2009 Results were reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top